Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight

This article was originally published in The Pink Sheet Daily

Executive Summary

Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.

You may also be interested in...



Greenwood: Future BIO Global Efforts Include International Relations

BIO joins forces with other national biotech associations to lobby the World Health Organization on intellectual property, innovation and public health.

Greenwood: Future BIO Global Efforts Include International Relations

BIO joins forces with other national biotech associations to lobby the World Health Organization on intellectual property, innovation and public health.

India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs

India's National Pharmaceutical Pricing Authority has imposed a 15-day deadline on 11 drug manufacturers to rein in costs of certain drugs, citing the "public interest" of lower prices for consumers

Related Content

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel